Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 9:56 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 756 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Raised Intraocular Pressure Clear all

Conditions: Healthy
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 45 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Primary Open-angle Glaucoma, Cataract
Interventions: CyPass Micro-Stent implanted with CyPass 241-S applier, Cataract surgery; Device · Procedure
Lead sponsor: Alcon Research; Industry
Eligibility: 45 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 20
States / cities: Phoenix, Arizona • Orange, California • Fort Collins, Colorado + 16 more

Conditions: Glaucoma; Drugs, Normal Tension Glaucoma, Primary Open-angle Glaucoma
Interventions: Timolol Maleate, Brimonidine Tartrate; Drug
Lead sponsor: Wills Eye; Other
Eligibility: 18 Years to 90 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Glaucoma
Interventions: Latanoprost, Placebo, RO5093151; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: Artesia, California • Aurora, Colorado • Morrow, Georgia + 3 more

Conditions: Glaucoma
Interventions: Visual field assessment; Diagnostic Test
Lead sponsor: Gainesville Eye Associates; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Gainesville, Georgia

Conditions: Glaucoma, Ocular Hypertension
Interventions: Preservative free tafluprost opthalmic solution; Drug
Lead sponsor: Santen Oy; Industry
Eligibility: 1 Month to 17 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Primary Open Angle Glaucoma or Ocular Hypertension
Interventions: AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.04%, AR-13324 Ophthalmic Solution Placebo; Drug
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 40
States / cities: Chandler, Arizona • Phoenix, Arizona • Azusa, California + 29 more

Conditions: Primary Open Angle Glaucoma, Ocular Hypertension
Interventions: ATS907; Drug
Lead sponsor: Altheos, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Artesia, California

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: Brimonidine Tartrate Ophthalmic Solution; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 2 Months and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Primary Open Angle Glaucoma
Interventions: Hydrus Aqueous Implant, Cataract surgery; Device · Procedure
Lead sponsor: Ivantis, Inc.; Industry
Eligibility: 45 Years and older
Enrollment: 1,143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 26
States / cities: Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 23 more

Conditions: Eye Diseases, Myopia, Glaucoma
Interventions: DREAM OCT; Device
Lead sponsor: Robert T. Chang, MD; Other
Eligibility: 18 Years and older
Enrollment: 154 participants
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Open Angle Glaucoma, Pigmentary Glaucoma, Pseudoexfoliation Glaucoma
Interventions: iStent infinite trabecular micro-bypass system model iS3, iDose TR (Travoprost intracameral Implant) 75mcg; Device · Drug
Lead sponsor: Jonathon Myers; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Primary Open-angle Glaucoma (POAG) Patient
Interventions: SENSIMED Triggerfish®; Device
Lead sponsor: Sensimed AG; Industry
Eligibility: 40 Years to 89 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Glaucoma
Interventions: Ahmed implant, Baerveldt implant; Device
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 85 Years
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Glaucoma
Interventions: fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution, fixed combination of dorzolamide hydrochloride timolol maleate ophthalmic solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 30 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: High Dose Drug Device, Low Dose Drug Device, Placebo Device, bimatoprost 0.03%; Drug
Lead sponsor: Vistakon Pharmaceuticals; Industry
Eligibility: 21 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 5
States / cities: Miami, Florida • Philadelphia, Pennsylvania • Mt. Pleasant, South Carolina + 2 more

Conditions: Glaucoma
Interventions: XEN Group, Phacoemulsification; Device · Procedure
Lead sponsor: Allergan; Industry
Eligibility: Not listed
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Irvine, California

Conditions: Primary Open-Angle Glaucoma
Interventions: Stents, Laser, Laser Trabeculoplasty; Device · Procedure
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 35 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 9
States / cities: Glendale, Arizona • Fayetteville, Arkansas • Hemet, California + 6 more

Conditions: Open Angle Glaucoma
Interventions: Transluminal viscoelastic delivery and trabeculotomy; Device
Lead sponsor: Sight Sciences, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 15
States / cities: Dothan, Alabama • Lake Havasu City, Arizona • Fayetteville, Arkansas + 12 more

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: Travoprost/brinzolamide; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: Artesia, California

Conditions: Glaucoma, Primary Open Angle
Interventions: Caffeine tablet; Dietary Supplement
Lead sponsor: Wills Eye; Other
Eligibility: 18 Years to 90 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Glaucoma
Interventions: Tube shunt surgery, Trabeculectomy, Mitomycin C; Procedure · Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 85 Years
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2021
U.S. locations: 12
States / cities: Sacramento, California • Gainesville, Florida • Miami, Florida + 9 more

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: PG324 Ophthalmic Solution 0.01%, PG324 Ophthalmic Solution 0.02%, Netarsudil (AR-13324) Ophthalmic Solution 0.02%, Latanoprost Ophthalmic Solution 0.005%; Drug
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 23
States / cities: Artesia, California • Inglewood, California • Newport Beach, California + 20 more

Conditions: Ocular Hypertension
Interventions: brimonidine/timolol fixed combination; Drug
Lead sponsor: Allergan; Industry
Eligibility: 21 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999
U.S. locations: 1
States / cities: Artesia, California

Search by objective public record fields.

Aqueous Outflow Facility Changes With Posture

Post Approval Study of the CyPass System

Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).

Comparison of Visual Field Assessments Between Three Perimeters

A Study to Evaluate Pharmacokinetics of Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients With Glaucoma or Ocular Hypertension

Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension

ATS907 Ph2a Open-Label Dose-ranging Safety and Tolerability in Primary Open Angle Glaucoma (POAG) and Ocular Hypertension (OHT) Subjects

A Phase III Study of Brimonidine Tartrate Ophthalmic Solution, 0.15% in Patients With Open-Angle Glaucoma or Ocular Hypertension

Safety & Effectiveness Study of the Hydrus Microstent for Lowering IOP in Glaucoma Patients Undergoing Cataract Surgery (HORIZON)

Swept Source OCT Imaging With the DREAM VG-OCT

Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma

Intraocular Pressure (IOP) Patterns in Fast Versus Slow Visual Field (VF) Progression Patients

Ahmed Versus Baerveldt Comparison Study

Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood Flow

Safety and Efficacy of a Drug Delivery System in Glaucoma

Chart Review of XEN 45 Gel Stent: Long Term Performance and Safety Assessment (XEN LT)

Multicenter Investigation of Trabecular Micro-Bypass Stents vs. Laser Trabeculoplasty

Study of OMNI System in OAG (GEMINI)

IOP Lowering Efficacy of Travoprost/Brinzolamide Fixed Combination Ophthalmic Suspension in Patients With Open-Angle Glaucoma or Ocular Hypertension

Caffeine Consumption in Glaucoma Patients and Healthy Subjects

Primary Tube Versus Trabeculectomy Study

Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure

Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension